Kooshki Fateme, Moradi Fardin, Karimi Arash, Niazkar Hamid Reza, Khoshbaten Manouchehr, Maleki Vahid, Pourghassem Gargari Bahram
Student Research Committee.
Nutrition Research Center, Department of Biochemistry & Diet Therapy, Faculty of Nutrition and Food Sciences, Tabriz University of Medical Sciences, Tabriz.
Eur J Gastroenterol Hepatol. 2021 Oct 1;33(10):1298-1306. doi: 10.1097/MEG.0000000000001830.
Nonalcoholic fatty liver disease (NAFLD) is a complicated disease and is considered as a severe global health problem affecting 30% of adults worldwide. The present study aimed to evaluate changes in oxidative stress, adipokines, liver enzyme, and body composition following treatment with chromium picolinate (CrPic) among patients with NAFLD.
The current randomized, double-blind, placebo-controlled study was conducted on 46 NAFLD patients with the age range of 20-65 years. Patients were randomly classified into two groups, receiving either 400 µg CrPic tablets in two divided doses of 200 µg (23 patients) or placebo (23 patients) daily for 12 weeks. The participants' body composition and biochemical parameters were evaluated at the baseline and after 12 weeks.
Serum levels of liver enzymes reduced significantly only in the CrPic group (P < 0.05 for all), but not between the groups after the intervention. Besides, there were significant differences between the study groups regarding body weight and body fat mass, total antioxidant capacity, superoxide dismutase, malondialdehyde, leptin, and adiponectin post-intervention (P = 0.017, P = 0.032, P = 0.003, P = 0.023, P = 0.012, P = 0.003, and P = 0.042, respectively). However, glutathione peroxidase and resistin levels did not differ significantly between groups (P = 0.127 and P = 0.688, respectively).
This study showed that consuming 400 µg/day of CrPic for 12 weeks in patients with NAFLD causes a significant change in leptin, adiponectin, oxidative stress (expect glutathione peroxidase), and body weight, compared to baseline. Nevertheless, it does not affect liver enzymes. Therefore, the CrPic supplementation may improve adipokines, some anthropometric indices, and oxidative stress in patients with NAFLD.
非酒精性脂肪性肝病（NAFLD）是一种复杂的疾病，被认为是一个严重的全球健康问题，影响着全球30%的成年人。本研究旨在评估吡啶甲酸铬（CrPic）治疗对NAFLD患者氧化应激、脂肪因子、肝酶和身体成分的影响。
本随机、双盲、安慰剂对照研究针对46名年龄在20 - 65岁的NAFLD患者进行。患者被随机分为两组，一组每天服用400μg CrPic片剂，分两次服用，每次200μg（23例患者），另一组服用安慰剂（23例患者），为期12周。在基线和12周后评估参与者的身体成分和生化参数。
仅CrPic组的血清肝酶水平显著降低（所有指标P < 0.05），但干预后两组之间无显著差异。此外，干预后研究组在体重、体脂肪量、总抗氧化能力、超氧化物歧化酶、丙二醛、瘦素和脂联素方面存在显著差异（分别为P = 0.017、P = 0.032、P = 0.003、P = 除谷胱甘肽过氧化物酶和抵抗素水平在两组之间无显著差异（分别为P = 0.127和P = 0.688）。
本研究表明，与基线相比，NAFLD患者每天服用400μg CrPic，持续12周，会使瘦素、脂联素、氧化应激（谷胱甘肽过氧化物酶除外）和体重发生显著变化。然而，它对肝酶没有影响。因此，补充CrPic可能改善NAFLD患者的脂肪因子、一些人体测量指标和氧化应激。 023、P = 0.012、P = 0.003和P = 0.042）。
